Thank you for your interest in Merriman Capital, Inc.’s U.S. equity research on Starpharma Holdings Ltd. (OTCQX: SPHRY). Please fill out and submit the electronic form below to immediately receive the research.
Merriman Capital, Inc. initiated research coverage on Starpharma in June 2007, rating its American Depositary Receipts (OTCQX: SPHRY) as a buy. The U.S. based investment bank also acts as the company’s Investment Bank Principal American Liaison (PAL) on the International OTCQX listing service.
Already registered: click here